Glenmark
A new way for a new world

April 03, 2012

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

We are enclosing herewith a press release informing "**Glenmark Generics receives ANDA approval for Desogestrel & Ethinyl Estradiol Tablets** ", for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Marshall Mendonza
Vice President & Company Secretary

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Encl: as above

Press Release For Immediate Release

Glenmark Generics receives ANDA approval for Desogestrel & Ethinyl Estradiol Tablets

- This is Glenmark's ninth Oral Contraceptive/hormone approval in the US

April 3, 2012: Glenmark Generics Inc., USA, a subsidiary of Glenmark Generics Ltd, today announced they have been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (U.S. FDA) for Desogestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP, 0.01 mg. Glenmark will market their approved product as Viorele™ Tablets and plan to commence shipping immediately.

Viorele™ Tablets are Glenmark's generic version of Mircette® tablets by Teva Women's Health Inc. Viorele™ is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

According to IMS Health for the 12 month period ending December 2011, the total market sales achieved for Desogestrel & Ethinyl Estradiol Tablets USP, 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP, 0.01 mg were approximately USD 98 million.

Today's approval marks Glenmark's ninth hormone/oral contraceptive product authorized for distribution by the U.S. FDA. Glenmark has a number of ANDA's currently pending approval with the U.S. FDA in this therapeutic segment as well as a sizeable concentration of their pipeline in various stages of development.

The Company's current portfolio consists of 78 generic products authorized for distribution in the U.S. market and 40 ANDA's filed with the U.S. FDA pending approval. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984 Email : connect@glenmark-generics.com